Utility of midpoint imaging in patients receiving peptide receptor radionuclide therapy (PRRT) for advanced progressive midgut neuroendocrine tumors (NET)

#3334

Introduction: The NETTER-1 trial formed the basis for standard practice of PRRT, consisting of 4 cycles with follow-up imaging during midtreatment and after completion to evaluate disease response. However, in clinical practice the timing of midpoint imaging varies if performed at all, and it is unclear how often it influences subsequent management.

Aim(s): To determine the frequency at which midpoint imaging is performed during PRRT in patients with primary GI NET, the imaging modality most used, and if imaging results changed subsequent clinical management.

Materials and methods: We reviewed patients at Mayo Clinic who started treatment with PRRT (Lu-177 DOTATATE) as of November 2020. Baseline patient demographics including oncology history were collected.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Norman A, Wee C, Hobday T, Kendi A, Johnson G,

Keywords: midpoint imaging, PRRT, clinical decision making,